. Author manuscript; available in PMC: 2016 Apr 26.

Published in final edited form as: Bone Marrow Transplant. 2012 Feb 13;47(10):1318–1320. doi: 10.1038/bmt.2012.10

Table 1. Patient characteristics.

Patients (n = 35)	Allo-SCT (n = 23)	Auto-SCT (n =12)	P-value
Median age (year)	52 (35 – 64)	61 (range 50 – 62)	0.012
Gender (male)	16 (70%)	8 (67%)	0.86
Stage			0.69
I and II	1 (4%)	4 (33%)
III and IV	22 (96%)	8 (67%)
Median number of extranodal sites	2 (0 – 3)	1 (0 – 2)	0.98
Median numbers of chemotherapy regimens	3 (1 – 6)	3 (2 – 5)	0.71
Rituximab maintenance pre-SCT			0.86
Yes	7 (30%)	4 (33%)
No	16 (70%)	8 (67%)
Disease status pre-SCT			0.93
CR	8 (35%)	4 (33%)
PR	15 (65%)	8 (67%)
Stem cell dose CD34+ cells/kg	7.35 × 10⁶ (range, 3.87–16.48)	2.8 × 10⁶ (range 2.3–9.8)	0.004